Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8527 as HIV-1 PrEP in women
PACTR202509662689795Phase 3Not yet recruiting
- Sponsor
- MSD
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of mk-8527 and emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV) (4 arms), sponsored by MSD. Primary endpoint: Adjudicated HIV-1 infection. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
mk-8527emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202509662689795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202509662689795.